Trends in psychotropic polypharmacy among youths enrolled in Ohio medicaid, 2002-2008

Psychiatric Services

Volumn 65, Issue 11, 2014, Pages 1332-1340

  Fontanella, Cynthia A ^a   Warner, Lynn A ^c   Phillips, Gary S ^b   Bridge, Jeffrey A ^b,d   Campo, John V ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADOLESCENT; ARTICLE; CONFIDENCE INTERVAL; DISABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; FAMILY; FOSTER CARE; HOUSEHOLD; HUMAN; INCOME; JUVENILE; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MEDICAID; MONITORING; POLYPHARMACY; PRESCRIPTION; PREVALENCE; TOTAL QUALITY MANAGEMENT; UNITED STATES; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISABLED PERSON; DRUG UTILIZATION; FEMALE; MALE; TRENDS;

ADOLESCENT; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DISABLED PERSONS; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MEDICAID; OHIO; POLYPHARMACY; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 84908645462     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201300410     Document Type: Article

References (55)

1. Chen H, Patel A, Sherer J, et al: The definition and prevalence of pediatric psychotropic polypharmacy. Psychiatric Services 62: 1450-1455, 2011
2. Comer JS, Olfson M, Mojtabai R: National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996- 2007. Journal of the American Academy of Child and Adolescent Psychiatry 49: 1001- 1010, 2010
3. McIntyre RS, Jerrell JM: Polypharmacy in children and adolescents treated for major depressive disorder: A claims database study. Journal of Clinical Psychiatry 70: 240-246, 2009
4. Duffy FF, Narrow WE, Rae DS, et al: Concomitant pharmacotherapy among youths treated in routine psychiatric practice. Journal of Child and Adolescent Psychopharmacology 15: 12-25, 2005
5. Connor DF, Ozbayrak KR, Kusiak KA, et al: Combined pharmacotherapy in children and adolescents in a residential treatment center. Journal of the American Academy of Child and Adolescent Psychiatry 36: 248-254, 1997
6. Pappadopulos E, Jensen PS, Schur SB, et al: "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophrenia Bulletin 28: 111-121, 2002
7. Zito JM, Safer DJ, Sai D, et al: Psychotropic medication patterns among youth in foster care. Pediatrics 121: E157-e163, 2008
8. Safer DJ, Zito JM, DosReis S: Concomitant psychotropic medication for youths. American Journal of Psychiatry 160: 438-449, 2003
9. Pruitt DBK, Laurel J: Psychiatric polypharmacy and children: Examining pediatric multipsychotropic regimens. Behavioral Health Management 24: S1-S4, 2004
10. Bartelink IH, Rademaker CMA, Schobben AF, et al: Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clinical Pharmacokinetics 45: 1077-1097, 2006
11. Technical Report on Psychiatric Polypharmacy. NASMHPD report 1-20. Alexandria, Va, National Association of State Mental Health Program Directors, 2001
12. Policy Statement: Prescribing Psychoactive Medication for Children and Adolescents. Washington, DC, American Academy of Child and Adolescent Psychiatry, Sept 20, 2001. Available at www.aacap.org/cs/root/policy-statements/prescribing-psychoactive-medication-for-children-and-adolescents
13. Wilens TE, Spencer T, Biederman J, et al: Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry 34: 110-112, 1995
14. Olfson M, Marcus SC, Weissman MM, et al: National trends in the use of psychotropic medications by children. Journal of the American Academy of Child and Adolescent Psychiatry 41: 514-521, 2002
15. dosReis S, Zito JM, Safer DJ, et al: Multiple psychotropic medication use for youths: A two-state comparison. Journal of Child and Adolescent Psychopharmacology 15: 68-77, 2005
16. dosReis S, Yoon Y, Rubin DM, et al: Antipsychotic treatment among youth in foster care. Pediatrics 128: E1459-e1466, 2011
17. dosReis S, Zito JM, Safer DJ, et al: Mental health services for youths in foster care and disabled youths. American Journal of Public Health 91: 1094-1099, 2001
18. Takayama JI, Bergman AB, Connell FA: Children in foster care in the state of Washington: Health care utilization and expenditures. JAMA 271: 1850-1855, 1994
19. Harman JS, Childs GE, Kelleher KJ: Mental health care utilization and expenditures by children in foster care. Archives of Pediatrics and Adolescent Medicine 154: 1114-1117, 2000
20. Kerker BD, Dore MM: Mental health needs and treatment of foster youth: Barriers and opportunities. American Journal of Orthopsychiatry 76: 138-147, 2006
21. Fincke BG, Snyder K, Cantillon C, et al: Three complementary definitions of polypharmacy: Methods, application and comparison of findings in a large prescription database. Pharmacoepidemiology and Drug Safety 14: 121-128, 2005
22. Essock SM, Covell NH, Leckman-Westin E, et al: Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. Psychiatric Services 60: 1595-1602, 2009
23. Parks J, Surles R: Using best practices to manage psychiatric medications under Medicaid. Psychiatric Services 55: 1227-1229, 2004
24. Stata Statistical Software: Release 12. College Station, Tex, StataCorp, 2011
25. Antidepressant use in children, adolescents, and adults [news release]. Washington, DC, US Food and Drug Administration, May 2, 2007. Available at www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096273.htm
26. Foster Children: HHS Guidance Could Help States Improve Oversight of Psychotropic Prescriptions: Report to Congressional Requesters. Pub no GAO-12-201. Washington, DC, US Government Accountability Office, Dec 15, 2011. Available at www.gao. gov/assets/590/586906.pdf
27. Rubin DM, Feudtner C, Localio R, et al: State variation in psychotropic medication use by foster care children with autism spectrum disorder. Pediatrics 124: E305-e312, 2009
28. Woolston JL: Combined pharmacotherapy: Pitfalls of treatment. Journal of the American Academy of Child and Adolescent Psychiatry 38: 1455-1457, 1999
29. Jellinek MS: Mirror, mirror on the wall: Are we prescribing the right psychotropic medications to the right children using the right treatment plan? [editorial]. Archives of Pediatrics and Adolescent Medicine 157: 14-16, 2003
30. Garland AF, Landsverk JA, Lau AS: Racial/ethnic disparities in mental health service use among children in foster care. Children and Youth Services Review 25: 491-507, 2003
31. Leslie LK, Hurlburt MS, Landsverk J, et al: Outpatient mental health services for children in foster care: A national perspective. Child Abuse and Neglect 28: 699-714, 2004
32. Rubin DM, Alessandrini EA, Feudtner C, et al: Placement stability and mental health costs for children in foster care. Pediatrics 113: 1336-1341, 2004
33. Rubin DM, Alessandrini EA, Feudtner C, et al: Placement changes and emergency department visits in the first year of foster care. Pediatrics 114: E354-e360, 2004
34. Crystal S, Olfson M, Huang C, et al: Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges. Health Affairs 28: W770-w781, 2009
35. Gören JL, Parks JJ, Ghinassi FA, et al: When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Joint Commission Journal on Quality and Patient Safety 34: 571-582, 2008
36. Constantine RJ, Boaz T, Tandon R: Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-forservice component of a large state Medicaid program. Clinical Therapeutics 32: 949-959, 2010
37. Stahl SM: Focus on antipsychotic polypharmacy: Evidence-based prescribing or prescribing-based evidence? International Journal of Neuropsychopharmacology 7: 113-116, 2004
38. Correll CU, Rummel-Kluge C, Corves C, et al: Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Bulletin 35: 443-457, 2009
39. McIntyre RS, Jerrell JM: Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Archives of Pediatrics and Adolescent Medicine 162: 929-935, 2008
40. Correll CU, Manu P, Olshanskiy V, et al: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302: 1765-1773, 2009
41. Correll CU: Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials. Journal of the American Academy of Child and Adolescent Psychiatry 46: 687-700, 2007
42. Information for Healthcare Professionals: Conventional Antipsychotics. Washington, DC, US Food and Drug Administration, 2011. Available at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ucm124830.htm
43. Kingsbury SJ, Yi D, Simpson GM: Psychopharmacology: Rational and irrational polypharmacy. Psychiatric Services 52: 1033-1036, 2001
44. Greydanus DE: Stimulant Misuse: Strategies to Manage a Growing Problem. Hanover, Md, American College Health Association Professional Development Program, 2006. Available at www.acha.org/prof-dev/ADHD-docs/ADHD-PDprogram-Article2.pdf
45. Wilens TE, Adler LA, Adams J, et al: Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry 47: 21-31, 2008
46. Wilens TE, Gignac M, Swezey A, et al: Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. Journal of the American Academy of Child and Adolescent Psychiatry 45: 408-414, 2006
47. Bhatara V, Feil M, Hoagwood K, et al: National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge. Journal of Attention Disorders 7: 217-226, 2004
48. Olfson M, Blanco C, Liu SM, et al: National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Archives of General Psychiatry 69: 1247-1256, 2012
49. Patel NC, Crismon ML, Hoagwood K, et al: Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 44: 548-556, 2005
50. Pliszka SR, Crismon ML, Hughes CW, et al: The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attentiondeficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 45: 642-657, 2006
51. Laita P, Cifuentes A, Doll A, et al: Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. Journal of Child and Adolescent Psychopharmacolology 17: 487-502, 2007
52. Sharp BW: Cmap ADHD and comorbid aggression algorithm. Journal of the American Academy of Child and Adolescent Psychiatry 46: 1-3, 2007
53. Levine JB, Deneys ML, Benjamin S: Dystonia with combined antipsychotic and stimulant treatment. Journal of the American Academy of Child and Adolescent Psychiatry 46: 665-666, 2007
54. Benjamin E, Salek S: Stimulant-atypical antipsychotic interaction and acute dystonia. Journal of the American Academy of Child and Adolescent Psychiatry 44: 510-512, 2005
55. Crystal S, Akincigil A, Bilder S, et al: Studying prescription drug use and outcomes with Medicaid claims data: Strengths, limitations, and strategies. Medical Care 45(suppl 2): S58-S65, 2007